BrainStorm Cell Therapeutics Engages Dr. Holly G. Atkinson.

NEW YORK & TEL AVIV, Israel -- BrainStorm Cell Therapeutics (OTCBB:BCLI) announced today that it has engaged Dr. Holly G. Atkinson, an experienced business executive and seasoned communications expert, to serve as the Company's Contract Director of Business Development. BrainStorm is developing stem cell therapeutic products for the treatment of neurodegenerative diseases.

"We are delighted to have an individual of Dr. Atkinson's outstanding caliber join our team," said Yoram Drucker, Chief Operations Officer and Principal Executive of BrainStorm. "Holly brings a unique blend of experience and skill to BrainStorm. She has business acumen, media savvy and medical expertise, which we are confident will help accelerate our Company's business development program."

Dr. Atkinson was a founder and President and CEO of Reuters Health Information. In addition, she has considerable experience with early-stage biotechnology companies, as well as with the media. She has published widely in consumer health publications and has extensive experience as a medical correspondent, including past assignments with NBC's Today show, The CBS Morning News, Lifetime Medical Television and the PBS health show BodyWatch.

In addition, Dr. Atkinson is an Assistant Professor of Public Health (courtesy) in the Division of Medical Ethics at the Weill Medical College of Cornell University. She is also the Editor-in-Chief of HealthNews and President of Physicians for Human Rights, a human rights organization.

Dr. Atkinson holds both an MD from the University of Rochester's School of Medicine and Dentistry and an MS degree in journalism from Columbia University's Graduate School of Journalism. She is also a Fellow of the American College of Physicians.

"I'm excited to be working with BrainStorm because the company's technology offers several advantages over other stem cell technologies," said Dr. Atkinson. "Because BrainStorm's cells are harvested from one's own adult bone marrow, the stem cells are easy to collect and do not present the ethical concerns that have been raised with embryonic stem cells. They are also safer, as they do not carry the risk of being rejected by the body. Ultimately, I believe these advantages provide BrainStorm with the opportunity to move its products to the market faster than many other companies, and thereby help patients sooner."

BrainStorm has successfully used bone marrow stem cells to produce dopaminergic-like cells shown to be capable of dopamine secretion and improvement of symptoms in animals with Parkinson's disease.

BrainStorm has also used its stem cell technology to produce astrocyte-like cells with the capacity of producing glial-derived neurotrophic factor (GDNF), the most potent neurotrophic factor known for dopaminergic neurons. Transplanted dopamine- and GDNF producing-cells, acting on their own or in combination, hold great promise for replacement and preservation of neurons in Parkinson's and other neurodegenerative diseases.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company developing neural-like stem cell therapeutic products, NurOwn(TM), based on autologous bone marrow-derived stromal cells, for treatment of neurodegenerative diseases. NurOwn(TM) patent pending technology is based on discoveries made by the team led by prominent neurologist Professor Eldad Melamed, Head of Neurology at Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University, enabling the differentiation of bone marrow derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The company's initial focus is on developing treatments for Parkinson's disease.

About Stem Cell Therapy 

Stem cells are non-specialized cells with a remarkable potential for both self-renewal and differentiation into cell types with a specialized function, such as muscle, blood or brain cells. Stem cells can be harvested from fetal or embryonic tissue or from adult tissue reservoirs such as bone marrow. Use of embryonic stem cells is at the center of significant ethical and moral debate. In contrast, use of adult stem cells does not provoke the same moral or legal controversy. Stem cell therapy aims to "cure" disease by replacing the diseased cells with healthy cells derived from stem cells. This approach has the potential to revolutionize medicine and, if successful, the implied commercial opportunities are great. Currently, scientists are exploring both embryonic stem cells (ESC) and adult stem cells (ASC) as the potential basis for multiple cell therapy products.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, risks associated with BrainStorm Cell Therapeutics Inc.'s limited operating history, history of losses and expectation to incur losses for the foreseeable future; limited cash resources and its need to raise additional capital to execute on its business plan and continue operations; transition issues related to the departure of its CEO; dependence on its license to Ramot's technology and ability to meet its funding and payment obligations included in such license agreement; ability, together with its licensor, to adequately protect the NurOwn(TM) technology; dependence on key executives and on its scientific consultants; ability to identify, negotiate and successfully implement strategic partnering relationships; ability to complete clinical trials successfully and to obtain required regulatory approvals; competition with companies, some of which have greater resources and experience in developing and obtaining regulatory approval for treatments in BrainStorm Cell Therapeutics Inc.'s market; the limited public trading market for BrainStorm Cell Therapeutics Inc.'s stock which may never develop into an active market; and other factors detailed in BrainStorm Cell Therapeutics Inc.'s annual report on Form 10-KSB, quarterly reports on Form 10-QSB, current reports on Form 8-K and other filings with the Securities and Exchange Commission available at http://www.sec.gov/ or by request to the Company. The Company does not undertake any obligation to update forward-looking statements made by us.